Skip to content

Precision Resuscitation With Crystalloids in Sepsis

Precision Resuscitation With Crystalloids in Sepsis (PRECISE)

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06253585
Acronym
PRECISE
Enrollment
2012
Registered
2024-02-12
Start date
2024-06-13
Completion date
2025-12-19
Last updated
2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

Algorithm, Fluids, Infection, Crystalloids, Normal Saline

Brief summary

Fluids are one of the most common treatments given to patients in the hospital. Fluids are especially important in treating patients with sepsis. Multiple clinical studies have compared the two main types of fluids used in sepsis (normal saline and balanced crystalloids). However, these studies have not found a clear benefit of one type of fluid versus the other. Which fluid should be given to which patient is an essential question because of the ubiquity of this intervention. Even a small difference in mortality could drastically change the standards of care given the national (and worldwide) scale of this intervention. The investigators have developed an algorithm that uses bedside vital signs (temperature, heart rate, respiratory rate, and blood pressure) to identify a group of patients (Group D) who have a significant mortality benefit from balanced crystalloids. The study randomizes adult patients admitted through emergency departments across 6 Emory hospitals belonging to Group D to intervention versus usual care. The intervention arm involves a prompt to clinicians to use balanced crystalloids rather than normal saline.

Detailed description

In this study, the vitals trajectory algorithm will run on all adult patients presenting to the emergency department (ED) across the Emory Healthcare hospitals. Patients will be enrolled and eligible for randomization once they meet suspicion of infection criteria. Suspicion of infection is defined broadly as the ordering of blood cultures in the emergency department. Group D patients with a blood culture order in whom clinicians initiate a normal saline order will be randomized within the electronic health record to either usual care or the intervention arm. In the intervention arm, if a clinician orders normal saline in a patient classified as Group D, there will be an EHR alert to change the order to balanced crystalloids (i.e., Lactated Ringer or Plasma-Lyte solution). The alert will announce that preliminary data suggests a mortality benefit from balanced crystalloids in this patient and will ask the clinician whether there is a strong clinical indication to use normal saline. The intervention is intended to start as early in the hospitalization as possible in the emergency department, as early crystalloid resuscitation choices may have effects on outcomes. The primary analysis is an intention-to-treat analysis (i.e., all patients randomized to intervention versus usual care regardless of whether the intervention resulted in a change in fluid choice). The intervention will be continued only for patients admitted from the emergency department to the intensive care unit. For patients in the intervention arm who are admitted to the ICU, the alert will fire every time normal saline is ordered till ICU discharge, death, or for up to 30 days of hospitalization. The intervention is necessarily unblinded when a clinician receives an alert when ordering normal saline on study patients.

Interventions

OTHERAlgorithm Alarm- Crystalloids

The study uses an algorithm implemented within the Electronic Health Record (EHR). This algorithm identifies patients who belong to a sepsis subphenotype known as "Group D", in whom published data has shown a mortality benefit from balanced crystalloids compared to normal saline. The intervention is an EHR alert when clinicians order normal saline on Group D patients randomized to intervention. In the intervention arm, if a clinician orders normal saline in a patient classified as Group D, there will be an EHR alert to change the order to balanced crystalloids (i.e., Lactated Ringer or Plasma-Lyte solution).

OTHERStandard of Care

Enrolled patients who are classified to Group D by the algorithm will be randomized within the electronic health record to usual care. In the usual care arm, the clinicians will not have any feedback from the algorithm and will not know the Group classification of their patient or the recommended fluid type.

Sponsors

Emory University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All adult patients presenting to the Emergency Department, with a blood culture order in the Emergency Department, who are classified as Group D, in whom a clinician initiates a normal saline order

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Thirty-day mortality30 daysThirty-day mortality

Secondary

MeasureTime frameDescription
Intensive care unit (ICU) admissionDuration of hospital stay up to 30 daysRate of ICU admission
In-hospital mortalityDuration of hospital stay, up to 30 daysRate of in-hospital mortality.
Use of vasoactive drugsDuration of hospital stay up to 30 daysProportion of patients requiring vasoactive drugs during hospital admission.
New renal replacement therapy (RRT)Duration of hospital stay up to 30 daysProportion of patients requiring (RRT) during hospital admission
Mechanical ventilationDuration of hospital stay up to 30 daysProportion of patients requiring mechanical ventilation during hospital admission.
EHR alert complianceDuration of hospital stay up to 30 daysEHR alert compliance will be measured by the number of changes in clinician intravenous fluid ordering pattern after an EHR alert.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORSivasubramanium Bhavani, MD

Emory University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026